Caspases-Dependent Cleavage of Mitotic Checkpoint Proteins in Response to Microtubule Inhibitor (original) (raw)
The mitotic checkpoint ensures the fidelity of chromosomal segregation by delaying the onset of anaphase until all chromosomes are aligned on the metaphase plate. After sustained mitotic arrest, however, cells eventually exit mitosis without the mitotic checkpoint being silenced. These cells then undergo apoptosis, an event that is important for prevention of the chromosomal instability observed in human cancers. An interesting question is to establish the biochemical link between the mitotic checkpoint and the subsequent apoptotic cell death. Here, we found that following prolonged spindle damage, the mitotic checkpoint kinases such as Bub1 and BubR1 were cleaved through a mechanism sensitive to caspases inhibitor. Interestingly, the expression of these mutants resistant to caspases-dependent cleavage led to increased apoptosis after sustained mitotic arrest, and a correspondingly more efficient elimination of the polyploid population than that seen in cells expressing wild-type proteins. These findings provide the novel biochemical properties of mitotic checkpoint proteins through its cleavage by caspases-dependent manner.
Keywords: Apoptotic cell death;Caspase-mediated cleavage;Mitotic checkpoint proteins;Polyploidy
Document Type: Research Article
Affiliations: 1: *Research Institute, National Cancer Center, Goyang, Gyeonggi, 411-764, Korea 2: Research Institute, National Cancer Center, Goyang, Gyeonggi, 411-764, Korea 3: Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
Publication date: 2005-03-01
More about this publication?
- Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
From Volume 23, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics is Open Access under the terms of the Creative Commons CC BY-NC-ND license. - Editorial Board
- Information for Authors
- Submit a Paper
- Ingenta Connect is not responsible for the content or availability of external websites